We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 01, 2020

Outcomes Superior With Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy

JNCI Cancer Spectrum

 

Additional Info

Disclosure statements are available on the authors' profiles:

JNCI Cancer Spectrum
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy
JNCI Cancer Spectr 2020 Feb 01;4(1)pkz085, HS Rugo, J Ettl, SA Hurvitz, A Gonçalves, KH Lee, L Fehrenbacher, LA Mina, S Diab, NE Woodward, R Yerushalmi, A Goodwin, JL Blum, M Martin, RGW Quek, IC Tudor, H Bhattacharyya, E Gauthier, JK Litton, W Eiermann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading